Scientists discover new cause of aggressive cancer in young people… and a possible treatment

According to a study, a little -known molecule in the body can usually be the key to treating aggressive cancer that usually strikes young people.

Researchers in New York have reviewed records from 11,000 cancer patients to evaluate non -encoding RNAs (LNCRNAs), a kind of RNA molecule that helps to regulate gene behavior and distinguish them from unhealthy cells.

When examining human breast tumor models, they found a specific type of LNCRNA called LINC01235, previously due to stomach cancer, and may be feeding breast cancer cells.

The team tested hypotheses using genus regulation to ‘close’ in cells from triple negative breast cancer (TNBC) cells, which is an aggressive form of an aggressive disease resistant to standard hormonal treatments.

They found that the LINC01235 -free cancer cells grow slower and that they were worse than those with active molecule in forming tumors.

Experts from the Cold Spring Harbor Laboratory in Long Island believe that LINC01235 has activated another gene called NFIB, which has shown that triple negative breast cancer risk.

NFIB then checks how the cells grow and develop, causing them to be cancer cells. By closing the molecule (LINC01235), which encourages TNBC (NFIB) to proliferate, researchers believe that tumor growth and spread.

David Spector, a study researcher, believes that the findings can lead to new treatments for triple negative breast cancer, which constitutes 10 to 15 percent of the diagnosis of breast cancer and disproportionately identified in young women.

Breanna Bortner, who was depicted with his dog Mochi, was diagnosed with an aggressive breast cancer with an aggressive breast cancer that starts in milk channels at 30.

He said: ‘Our long -term goal is to try to find a lncrna or more than one lncrna that can eventually be therapeutic goals.’

Breast cancer is the most common cancer among women, affects 316,000 a year and kills 42,000 in the USA.

It is negative up to about 10 to 15 percent of breast cancers and adds 47,000 cases and 6,300 deaths.

The triple negative means that cancer cells do not have estrogen and progesterone hormones and receptors that respond to her-2 protein.

Without these receptors, triple negative breast cancers do not respond to the treatments targeting these hormones and make it difficult for them to be treated.

If the survival rate is over 90 percent if caught in previous stages, the disease falls up to 15 percent when the disease spreads to lymph nodes and other organs.

It is the most common in black women and women under 40 years of age, and it is one of the many forms of the disease on rising with column and lung cancers.

In the new study, Molecular Cancer ResearchTumor samples were taken from breast cancer patients in New York and used to make organoids, small tumor models. It was then compared with healthy tissue samples.

After finding a lump on her chest, Holly McCabe was diagnosed with a 30 -year -old triple negative breast cancer.

Researchers found that the expressions of LINC01235 of breast cancer tumors were significantly higher than healthy tissue.

LINC01235 was then disabled with CRISPR, a type of gene regulation, mostly head, neck, gastrointestinal and tested in brain cancers.

When the researchers disable LINC01235, the tumor growth slowed down, and the team suspected that the molecule increased the growth of breast cancer cells.

They suspected that LINC01235 activated Gen NFIB, which is mostly connected to triple negative breast cancer compared to breast cancer forms.

NFIB is believed to suppress P21 expression, a protein that inhibits cell growth.

When this protein is suppressed, cancer cells can grow uncontrollably.

Stony Brook University graduate student chief researcher Wenbo XU said, ‘Our findings show that LINC01235 regulates NFIb transcription.’

The team said that the findings could be the first step to develop CRISPR technology to treat triple negative breast cancer.